PuraPharm Corp Ltd
HKEX:1498
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
PuraPharm Corp Ltd's latest stock split occurred on Jan 29, 2020
The company executed a 18-for-17 stock split, meaning that for every 17 shares held, investors received 18 new shares.
Before the split, PuraPharm Corp Ltd traded at 0.96 per share. Afterward, the share price was about 0.94.
The adjusted shares began trading on Jan 29, 2020. This was the only stock split in PuraPharm Corp Ltd's history.
Global
Stock Splits Monitor
| Date | Company | Split | Pre-Split Price | Post-Split Price | |
|---|---|---|---|---|---|
|
Apr 24, 2026
|
|
Cue Biopharma Inc
NASDAQ:CUE
|
1-for-30
/30
|
0.5542 16.626 USD | 17.695 17.695 USD |
|
Apr 24, 2026
|
|
Medical Data Vision Co Ltd
TSE:3902
|
2-for-7253607
/3626803.5
|
1684 1684 JPY | N/A |
|
Apr 24, 2026
|
E
|
ESGL Holdings Ltd
NASDAQ:ESGL
|
1-for-3
/3
|
2.35 7.05 USD | 2.93 2.93 USD |
|
Apr 24, 2026
|
|
Metro Mining Ltd
ASX:MMI
|
1-for-20
/20
|
0.067 1.34 AUD | 1.3 1.3 AUD |
|
Apr 24, 2026
|
L
|
La Comer SAB de CV
OTC:LCMRF
|
115-for-114
x1.0087719298246
|
2.4715 2.4341 USD | 2.45 2.45 USD |
CUE
3902
MMI
PuraPharm Corp Ltd
Glance View
PuraPharm Corp. Ltd. is an investment holding company, which engages in the research and development, production and sale of concentrated Chinese medicine granule (CCMG) products and Chinese healthcare products, as well as rendering of Chinese medical diagnostic services. The firm operates through five business segments. The China CCMG segment is mainly engaged in the production and sales of CCMG products in China. The Hong Kong CCMG segment is mainly engaged in the sales of CCMG products, excluding the sales through self-operated clinics in Hong Kong. The Chinese Healthcare Products segment is mainly engaged in the production and sales of healthcare products in Hong Kong and China. The Clinics segment is mainly engaged in the provision of Chinese medical diagnostic services and sales of CCMG products through self-operated clinics. The Plantation segment is mainly engaged in the plantation and trading of raw Chinese herbs, and the manufacture and sale of traditional Chinese medicine (TCM) decoction pieces.
